Last updated: 13 November 2023 at 7:36pm EST

Sachs Group Incgoldman Sach... Net Worth




The estimated Net Worth of Sachs Group Incgoldman Sach... is at least $239 Million dollars as of 8 November 2023. Sachs Sach owns over 72,874 units of Panbela Therapeutics stock worth over $139,284 and over the last 21 years Sachs sold PBLA stock worth over $239,049,217.

Sachs Sach PBLA stock SEC Form 4 insiders trading

Sachs has made over 48 trades of the Panbela Therapeutics stock since 2005, according to the Form 4 filled with the SEC. Most recently Sachs sold 72,874 units of PBLA stock worth $51,741 on 8 November 2023.

The largest trade Sachs's ever made was selling 5,243,185 units of Panbela Therapeutics stock on 17 May 2012 worth over $197,038,892. On average, Sachs trades about 98,247 units every 72 days since 2003. As of 8 November 2023 Sachs still owns at least 397,954 units of Panbela Therapeutics stock.

You can see the complete history of Sachs Sach stock trades at the bottom of the page.



What's Sachs Sach's mailing address?

Sachs's mailing address filed with the SEC is 200 WEST STREET200 WEST STREET, , NEW YORKNEW YORK, NYNY, 1028210282.

Insiders trading at Panbela Therapeutics

Over the last 4 years, insiders at Panbela Therapeutics have traded over $51,741 worth of Panbela Therapeutics stock and bought 406,888 units worth $0 . The most active insiders traders include Sachs Group Incgoldman Sach..., Donald Robert Schemel, and Michael T. Cullen. On average, Panbela Therapeutics executives and independent directors trade stock every 67 days with the average trade being worth of $27,986. The most recent stock trade was executed by Sachs Group Incgoldman Sach... on 8 November 2023, trading 72,874 units of PBLA stock currently worth $51,741.



What does Panbela Therapeutics do?

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.



What does Panbela Therapeutics's logo look like?

Panbela Therapeutics Inc. logo

Complete history of Sachs Sach stock trades at Ambarella Inc, Benefitfocus Inc, Endurance International Inc, Extraction Oil & Gas Inc, Meta Platforms Inc, Moneygram International, MYR Inc, Prime Resources Corp, T2 Biosystems Inc, Tiptree Inc, Viveve Medical Inc, Aramark, Core Laboratories Inc, CVR Inc, Dollar General, Enlink Midstream, Hexcel, Hyatt Hotels, Openlane, Kinder Morgan Inc, Lazard, MRC Global Inc, Mesa Air, Rekor Systems Inc, Prosight Global Inc, Kingswood Acquisition, and Panbela Therapeutics

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
8 Nov 2023 Sachs Group Incgoldman Sach...
Sale 72,874 $0.71 $51,741
8 Nov 2023
397,954
31 Aug 2022 Sachs Group Incgoldman Sach...
Sale 53,000 $10.29 $545,370
31 Aug 2022
96,416
12 May 2021 Sachs Group Incgoldman Sach...
Sale 400,000 $10.03 $4,012,000
12 May 2021
3,936,957
1 Apr 2020 Sachs Group Incgoldman Sach...
Buy 676 $9.34 $6,314
1 Apr 2020
4,640,900
25 Mar 2020 Sachs Group Incgoldman Sach...
Sale 3,601 $47.93 $172,596
25 Mar 2020
40,299
29 Nov 2019 Sachs Group Incgoldman Sach...
Sale 7,001 $1.46 $10,221
29 Nov 2019
10,624,314
30 Sep 2019 Sachs Group Incgoldman Sach...
Sale 92,425 $4.81 $444,564
30 Sep 2019
0
20 Sep 2019 Sachs Group Incgoldman Sach...
Buy 64,200 $5.76 $369,792
20 Sep 2019
115,584
9 Aug 2019 Sachs Group Incgoldman Sach...
Buy 8,083 $18.30 $147,919
9 Aug 2019
17,602,384
1 Feb 2019 Sachs Group Incgoldman Sach...
Buy 24,791 $10.86 $269,230
1 Feb 2019
720,423
29 Dec 2016 Sachs Group Incgoldman Sach...
Buy 400 $56.23 $22,492
29 Dec 2016
114,451
1 Dec 2014 Sachs Group Incgoldman Sach...
Buy 392 $58.25 $22,834
1 Dec 2014
82,409
7 Aug 2012 Sachs Group Incgoldman Sach...
Buy 100 $38.20 $3,820
7 Aug 2012
21,884
7 Jul 2016 Sachs Group Incgoldman Sach...
Buy 1,422 $9.01 $12,812
7 Jul 2016
15,378,521
26 Jun 2015 Sachs Group Incgoldman Sach...
Buy 400 $20.49 $8,196
26 Jun 2015
15,378,521
20 Apr 2015 Sachs Group Incgoldman Sach...
Buy 300 $22.56 $6,768
20 Apr 2015
15,378,421
11 Feb 2015 Sachs Group Incgoldman Sach...
Buy 4,700 $31.28 $147,016
11 Feb 2015
26,547,689
12 Jun 2014 Sachs Group Incgoldman Sach...
Buy 471 $26.02 $12,255
12 Jun 2014
34,833,006
26 Jan 2015 Sachs Group Incgoldman Sach...
Sale 16,030 $7.39 $118,462
26 Jan 2015
5,631,956
2 Jan 2015 Sachs Group Incgoldman Sach...
Sale 22,300 $7.64 $170,372
2 Jan 2015
5,636,980
10 Dec 2014 Sachs Group Incgoldman Sach...
Buy 73,165 $7.87 $575,809
10 Dec 2014
5,648,500
18 Nov 2014 Sachs Group Incgoldman Sach...
Buy 12,193 $7.69 $93,764
18 Nov 2014
5,609,447
28 Oct 2014 Sachs Group Incgoldman Sach...
Sale 8,941 $7.96 $71,170
28 Oct 2014
5,607,047
7 Oct 2014 Sachs Group Incgoldman Sach...
Sale 16,794 $7.33 $123,100
7 Oct 2014
5,609,068
17 Sep 2014 Sachs Group Incgoldman Sach...
Sale 127,628 $7.95 $1,014,643
17 Sep 2014
5,609,053
26 Aug 2014 Sachs Group Incgoldman Sach...
Buy 35,012 $7.62 $266,791
26 Aug 2014
5,608,473
5 Aug 2014 Sachs Group Incgoldman Sach...
Sale 14,264 $7.12 $101,560
5 Aug 2014
5,596,353
17 Jul 2014 Sachs Group Incgoldman Sach...
Buy 200 $40.10 $8,020
17 Jul 2014
11,380,801
28 Mar 2013 Sachs Group Incgoldman Sach...
Buy 6,049 $32.58 $197,076
28 Mar 2013
29,088,257
17 May 2012 Sachs Group Incgoldman Sach...
Sale 5,243,185 $37.58 $197,038,892
17 May 2012
8,971,622
6 Mar 2012 Sachs Group Incgoldman Sach...
Buy 258 $37.09 $9,569
6 Mar 2012
0
2 Mar 2011 Sachs Group Incgoldman Sach...
Buy 100 $30.56 $3,056
2 Mar 2011
0
7 Dec 2011 Sachs Group Incgoldman Sach...
Buy 100 $39.06 $3,906
7 Dec 2011
46,413,692
24 May 2011 Sachs Group Incgoldman Sach...
Buy 80 $32.73 $2,618
24 May 2011
52,476,465
16 May 2011 Sachs Group Incgoldman Sach...
Buy 140 $33.50 $4,690
16 May 2011
52,476,465
14 Dec 2010 Sachs Group Incgoldman Sach...
Buy 1,800 $30.65 $55,170
14 Dec 2010
52,476,465
20 Nov 2009 Sachs Group Incgoldman Sach...
Buy 200 $23.15 $4,630
20 Nov 2009
64,991,987
13 Nov 2009 Sachs Group Incgoldman Sach...
Buy 13,500 $22.90 $309,150
13 Nov 2009
68,571,395
15 Nov 2011 Sachs Group Incgoldman Sach...
Buy 25,916 $19.01 $492,663
15 Nov 2011
27,425
10 Jan 2011 Sachs Group Incgoldman Sach...
Buy 8,153 $15.30 $124,741
10 Jan 2011
15,121,607
1 Aug 2008 Sachs Group Incgoldman Sach...
Sale 669 $15.95 $10,671
1 Aug 2008
31,433,560
25 Oct 2007 Sachs Group Incgoldman Sach...
Buy 100 $22.00 $2,200
25 Oct 2007
31,433,460
1 Aug 2008 Sachs Group Incgoldman Sach...
Sale 35 $61.91 $2,167
1 Aug 2008
623,521
21 Sep 2005 Sachs Group Incgoldman Sach...
Buy 360 $17.76 $6,394
21 Sep 2005
6,260


Panbela Therapeutics executives and stock owners

Panbela Therapeutics executives and other stock owners filed with the SEC include: